Supplemental material Systems Pharmacology Approach to Prevent Retinal Degeneration in Stargardt Disease Yu Chen, Grazyna Palczewska, Debarshi Mustafi, Marcin Golczak, Zhiqian Dong, Osamu Sawada, Tadao Maeda, Akiko Maeda, and Krzysztof Palczewski Table of Contents: 1. Supplemental Table 1. 2. Supplemental Table 2. 3. Supplemental Table 3. 4. References. Supplemental Table 1. Expression of GPCRs in the eye and retina of C57BL/6J mice and the
retina of a human donor eye (normalized FPKM values)A.
Human retina Adcyap1r1
AAnalyses were done as described in Materials and Methods. Transcriptome data were used to
determine reads per kilobase of gene product per million reads (RPKM) for normalization and
differential expression analyses. Higher expression values in the retina relative to the eye
indicate their enrichment in retina. Such high values highlight those GPCRs that may be critical
in the eye and retina for drug discovery and therapeutic approaches. Both processed and raw
fastq files for transcriptome analyses were deposited in GEO (accession numbers GSE29752
Supplemental Table 2. Summary of pharmacologic agents targeting multiple GPCRs examined in the Abca4-/- Rdh8-/- mouse bright light-induced retinopathy modelA. Major action Efficacy Dose per Brand name/ Application
AVarious pharmacologic agents targeting multiple classes of GPCRs were examined for their effects on bright light-induced retinopathy in 4 to 5-week-old Abca4-/-Rdh8-/- mice. The name, major mechanism of action, efficacy (% of mice manifesting well-preserved retinal structure revealed by OCT imaging), dose and current clinical applications are indicated.
Supplemental Table 3. Chemical structure of the pharmacologic agents coupling with multiple GPCRs
examined in the Abca4-/-Rdh8-/- mouse bright light-induced retinopathy model.
GPCR coupling Chemical structure References
Guglielmo, R., Martinotti, G., Di Giannantonio, M., and Janiri, L. 2013. A possible new
option for migraine management: agomelatine. Clin Neuropharmacol. 36:65-67. doi:
de Bodinat, C., Guardiola-Lemaitre, B., Mocaer, E., Renard, P., Munoz, C., and Millan,
M.J. 2010. Agomelatine, the first melatonergic antidepressant: discovery, characterization and
development. Nat Rev Drug Discov. 9:628-642. doi: 610.1038/nrd3140. Epub 2010 Jun 1025.
Hemrick-Luecke, S.K., Snoddy, H.D., and Fuller, R.W. 1994. Evaluation of nefazodone
as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci. 55:479-483.
Chanrion, B., Mannoury la Cour, C., Gavarini, S., Seimandi, M., Vincent, L., Pujol, J.F.,
Bockaert, J., Marin, P., and Millan, M.J. 2008. Inverse agonist and neutral antagonist actions of
antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential
modulation of cell surface expression and signal transduction. Mol Pharmacol. 73:748-757.
Cusack, B., Nelson, A., and Richelson, E. 1994. Binding of antidepressants to human
brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 114:559-
Schipper, J., Tulp, M.T., and Sijbesma, H. 1990. Neurochemical profile of eltoprazine.
Drug Metabol Drug Interact. 8:85-114.
Gommans, J., Hijzen, T.H., Maes, R.A., and Olivier, B. 1997. Discriminative stimulus
properties of eltoprazine. Life Sci. 61:11-19.
D'Amico, J.M., Murray, K.C., Li, Y., Chan, K.M., Finlay, M.G., Bennett, D.J., and
Gorassini, M.A. 2013. Constitutively active 5-HT2/alpha1 receptors facilitate muscle spasms
after human spinal cord injury. J Neurophysiol. 109:1473-1484. doi: 1410.1152/jn.00821.02012.
Qiu, F., Qiu, C.Y., Liu, Y.Q., Wu, D., Li, J.D., and Hu, W.P. 2012. Potentiation of acid-
sensing ion channel activity by the activation of 5-HT(2) receptors in rat dorsal root ganglion
neurons. Neuropharmacology. 63:494-500. doi: 410.1016/j.neuropharm.2012.1004.1034. Epub
Toll, L., Berzetei-Gurske, I.P., Polgar, W.E., Brandt, S.R., Adapa, I.D., Rodriguez, L.,
Schwartz, R.W., Haggart, D., O'Brien, A., White, A., et al. 1998. Standard binding and functional
assays related to medications development division testing for potential cocaine and opiate
narcotic treatment medications. NIDA Res Monogr. 178:440-466.
Glusa, E., and Pertz, H.H. 2000. Further evidence that 5-HT-induced relaxation of pig
pulmonary artery is mediated by endothelial 5-HT(2B) receptors. Br J Pharmacol. 130:692-698.
Roscetti, G., Del Carmine, R., Trabucchi, M., Massotti, M., Purdy, R.H., and Barbaccia,
M.L. 1998. Modulation of neurosteroid synthesis/accumulation by L-ascorbic acid in rat brain
tissue: inhibition by selected serotonin antagonists. J Neurochem. 71:1108-1117.
Prins, N.H., Briejer, M.R., and Schuurkes, J.A. 1997. Characterization of the contraction
to 5-HT in the canine colon longitudinal muscle. Br J Pharmacol. 120:714-720.
Eglen, R.M., Bley, K., Bonhaus, D.W., Clark, R.D., Hegde, S.S., Johnson, L.G., Leung,
E., and Wong, E.H. 1993. RS 23597-190: a potent and selective 5-HT4 receptor antagonist. Br
Schiavi, G.B., Brunet, S., Rizzi, C.A., and Ladinsky, H. 1994. Identification of serotonin
5-HT4 recognition sites in the porcine caudate nucleus by radioligand binding.
Galeotti, N., Ghelardini, C., and Bartolini, A. 1998. Role of 5-HT4 receptors in the mouse
passive avoidance test. J Pharmacol Exp Ther. 286:1115-1121.
Hegde, S.S., Bonhaus, D.W., Johnson, L.G., Leung, E., Clark, R.D., and Eglen, R.M.
1995. RS 39604: a potent, selective and orally active 5-HT4 receptor antagonist. Br J
Medhurst, A.D., and Kaumann, A.J. 1993. Characterization of the 5-HT4 receptor
mediating tachycardia in piglet isolated right atrium. Br J Pharmacol. 110:1023-1030.
Sleight, A.J., Boess, F.G., Bos, M., Levet-Trafit, B., Riemer, C., and Bourson, A. 1998.
Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human
and rat 5-HT6 receptors. Br J Pharmacol. 124:556-562.
Bentley, J.C., Bourson, A., Boess, F.G., Fone, K.C., Marsden, C.A., Petit, N., and
Sleight, A.J. 1999. Investigation of stretching behaviour induced by the selective 5-HT6 receptor
antagonist, Ro 04-6790, in rats. Br J Pharmacol. 126:1537-1542.
Fone, K.C. 2008. An update on the role of the 5-hydroxytryptamine6 receptor in
cognitive function. Neuropharmacology.
1010.1016/j.neuropharm.2008.1006.1061. Epub 2008 Jul 1014.
Wesolowska, A., and Nikiforuk, A. 2007. Effects of the brain-penetrant and selective 5-
HT6 receptor antagonist SB-399885 in animal models of anxiety and depression.
Neuropharmacology. 52:1274-1283. Epub 2007 Jan 1220.
Romero, G., Sanchez, E., Pujol, M., Perez, P., Codony, X., Holenz, J., Buschmann, H.,
and Pauwels, P.J. 2006. Efficacy of selective 5-HT6 receptor ligands determined by monitoring
5-HT6 receptor-mediated cAMP signaling pathways. Br J Pharmacol. 148:1133-1143. Epub
Kim, H.J., Doddareddy, M.R., Choo, H., Cho, Y.S., No, K.T., Park, W.K., and Pae, A.N.
2008. New serotonin 5-HT(6) ligands from common feature pharmacophore hypotheses. J Chem Inf Model. 48:197-206. Epub 2007 Nov 2029.
Hagan, J.J., Price, G.W., Jeffrey, P., Deeks, N.J., Stean, T., Piper, D., Smith, M.I.,
Upton, N., Medhurst, A.D., Middlemiss, D.N., et al. 2000. Characterization of SB-269970-A, a
selective 5-HT(7) receptor antagonist. Br J Pharmacol. 130:539-548.
Lovell, P.J., Bromidge, S.M., Dabbs, S., Duckworth, D.M., Forbes, I.T., Jennings, A.J.,
King, F.D., Middlemiss, D.N., Rahman, S.K., Saunders, D.V., et al. 2000. A novel, potent, and
selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl)
phen ol (SB-269970). J Med Chem. 43:342-345.
Cushing, D.J., Zgombick, J.M., Nelson, D.L., and Cohen, M.L. 1996. LY215840, a high-
affinity 5-HT7 receptor ligand, blocks serotonin-induced relaxation in canine coronary artery. J Pharmacol Exp Ther. 277:1560-1566.
Lenglet, S., Louiset, E., Delarue, C., Vaudry, H., and Contesse, V. 2002. Activation of 5-
HT(7) receptor in rat glomerulosa cells is associated with an increase in adenylyl cyclase activity
and calcium influx through T-type calcium channels. Endocrinology. 143:1748-1760.
Alabaster, V.A., and Davey, M.J. 1986. The alpha 1-adrenoceptor antagonist profile of
doxazosin: preclinical pharmacology. Br J Clin Pharmacol. 21:9S-17S.
Mathe, J.M., Nomikos, G.G., Hildebrand, B.E., Hertel, P., and Svensson, T.H. 1996.
Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus
accumbens. Eur J Pharmacol. 309:1-11.
Pickering, D.S., and Niles, L.P. 1990. Pharmacological characterization of melatonin
binding sites in Syrian hamster hypothalamus. Eur J Pharmacol. 175:71-77.
Garcia-Sainz, J.A., Romero-Avila, M.T., Villalobos-Molina, R., and Minneman, K.P.
1995. Alpha 1-adrenoceptor subtype selectivity of tamsulosin: studies using livers from different
species. Eur J Pharmacol. 289:1-7.
Taguchi, K., Saitoh, M., Sato, S., Asano, M., and Michel, M.C. 1997. Effects of
tamsulosin metabolites at alpha-1 adrenoceptor subtypes. J Pharmacol Exp Ther. 280:1-5.
Tsuchida, A., Liu, Y., Liu, G.S., Cohen, M.V., and Downey, J.M. 1994. alpha 1-
adrenergic agonists precondition rabbit ischemic myocardium independent of adenosine by
direct activation of protein kinase C. Circ Res. 75:576-585.
Heinonen, I., Wendelin-Saarenhovi, M., Kaskinoro, K., Knuuti, J., Scheinin, M., and
Kalliokoski, K.K. 2013. Inhibition of alpha-adrenergic tone disturbs the distribution of blood flow
in the exercising human limb. Am J Physiol Heart Circ Physiol 10:10.
Evans, R.G., and Anderson, W.P. 1995. Renal effects of infusion of rilmenidine and
guanabenz in conscious dogs: contribution of peripheral and central nervous system alpha 2-
adrenoceptors. Br J Pharmacol. 116:1557-1570.
Holmes, B., Brogden, R.N., Heel, R.C., Speight, T.M., and Avery, G.S. 1983.
Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in
Intengan, H.D., and Smyth, D.D. 1997. Alpha-2a/d adrenoceptor subtype stimulation by
guanfacine increases osmolar clearance. J Pharmacol Exp Ther. 281:48-53.
Gish, E.C., Miller, J.L., Honey, B.L., and Johnson, P.N. 2010. Lofexidine, an {alpha}2-
receptor agonist for opioid detoxification. Ann Pharmacother.
310.1345/aph.1341M1347. Epub 2009 Dec 1329.
Honey, B.L., Benefield, R.J., Miller, J.L., and Johnson, P.N. 2009. Alpha2-receptor
agonists for treatment and prevention of iatrogenic opioid abstinence syndrome in critically ill
patients. Ann Pharmacother. 43:1506-1511. doi: 1510.1345/aph.1501M1161. Epub 2009 Aug
Markham, A., and Wagstaff, A.J. 1998. Fexofenadine. Drugs. 55:269-274; discussion
Gillard, M., and Chatelain, P. 2006. Changes in pH differently affect the binding
properties of histamine H1 receptor antagonists. Eur J Pharmacol. 530:205-214. Epub 2006 Jan
Nilvebrant, L., Andersson, K.E., Gillberg, P.G., Stahl, M., and Sparf, B. 1997.
Tolterodine--a new bladder-selective antimuscarinic agent. Eur J Pharmacol. 327:195-207.
Cowart, M., Latshaw, S.P., Bhatia, P., Daanen, J.F., Rohde, J., Nelson, S.L., Patel, M.,
Kolasa, T., Nakane, M., Uchic, M.E., et al. 2004. Discovery of 2-(4-pyridin-2-ylpiperazin-1-
ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for
the potential treatment of erectile dysfunction. J Med Chem. 47:3853-3864.
Glase, S.A., Akunne, H.C., Georgic, L.M., Heffner, T.G., MacKenzie, R.G., Manley, P.J.,
Pugsley, T.A., and Wise, L.D. 1997. Substituted [(4-phenylpiperazinyl)-methyl]benzamides:
selective dopamine D4 agonists. J Med Chem. 40:1771-1772.
Villamil-Hernandez, M.T., Alcantara-Vazquez, O., Sanchez-Lopez, A., and Centurion, D.
2013. Pharmacological identification of alpha- and alpha-adrenoceptor subtypes involved in the
vasopressor responses induced by ergotamine in pithed rats. Eur J Pharmacol 22:00388-00389.
Shi, W.X., and Bunney, B.S. 1992. Roles of intracellular cAMP and protein kinase A in
the actions of dopamine and neurotensin on midbrain dopamine neurons. J Neurosci. 12:2433-
Flacco, N., Segura, V., Perez-Aso, M., Estrada, S., Seller, J.F., Jimenez-Altayo, F.,
Noguera, M.A., D'Ocon, P., Vila, E., and Ivorra, M.D. 2013. Different beta-adrenoceptor
subtypes coupling to cAMP or NO/cGMP pathways: implications in the relaxant response of rat
conductance and resistance vessels. Br J Pharmacol. 169:413-425. doi: 410.1111/bph.12121.
Head lice infestations: A clinical update Français en page 699 Head lice ( Pediculus humanus capitis ) infestations remain apesky communicable problem, particularly in school-agechildren in Canada and elsewhere (1,2). A small 2003population-based study (3) of primary school children in theUnited Kingdom noted a 2% prevalence and a 37% annualincidence of head lice. Unlike body lice, hea